Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled Trial to Evaluate the Optimal Dose of MV-LASV, a New Vaccine Against LASSA Virus Infection, Regarding Safety, Tolerability & Immunogenicity in Healthy Volunteers Consisting of an Unblinded Dose Escalation & an Observer-blinded Treatment Phase

Trial Profile

A Randomized, Placebo-controlled Trial to Evaluate the Optimal Dose of MV-LASV, a New Vaccine Against LASSA Virus Infection, Regarding Safety, Tolerability & Immunogenicity in Healthy Volunteers Consisting of an Unblinded Dose Escalation & an Observer-blinded Treatment Phase

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lassa fever vaccine (Primary)
  • Indications Lassa fever
  • Focus Adverse reactions; First in man
  • Sponsors Themis Bioscience
  • Most Recent Events

    • 29 Oct 2019 According to an Themis Bioscience media release, this MV-LASV Lassa fever vaccine program is funded through a global partnership with CEPI that will support the candidate vaccine's development up to the end of Phase 2, which is designed to provide clinical safety and immunological data.
    • 29 Oct 2019 Status changed from not yet recruiting to recruiting, according to an Themis Bioscience media release.
    • 29 Oct 2019 According to an Themis Bioscience media release, the company announced the first administration to healthy volunteers in this study with Themis's vaccine candidate against Lassa fever.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top